SPARC expression in resected pancreatic cancer patients treated with gemcitabine: results from the CONKO-001 study
Authors:
- B. V. SinnBSB. V. Sinn
- J. K. StrieflerJSJ. K. Striefler
- J. L. LindnerJLJ. L. Lindner
- J. M. StielerJSJ. M. Stieler
- P. LohneisPLP. Lohneis
- S. BischoffSBS. Bischoff
- H. BläkerHBH. Bläker
- U. PelzerU. Pelzer
- M. BahraMBM. Bahra
- M. DietelMDM. Dietel
- B. DörkenBDB. Dörken
Open Access
- 20 February 2014
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 25 (5) , 1025-1032
Abstract
Previous investigations in pancreatic cancer suggested a prognostic role for secreted protein acidic and rich in cysteine (SPARC) expression in the peritumoral stroma but not for cytoplasmic SPARC expression. The aim of this study was to evaluate the impact of SPARC expression in pancreatic cancer patients treated with gemcitabine compared with untreated patients. CONKO-001 was a prospective randomized phase III study investigating the role of adjuvant gemcitabine when compared with observation. Tissue samples of 160 patients were available for SPARC immunohistochemistry on tissue microarrays to evaluate its impact on patient outcome. Strong stromal SPARC expression was associated with worse disease-free survival (DFS) and overall survival (OS) in the overall study population (DFS: P = 0.005, OS: P = 0.033). Its negative prognostic impact was restricted to patients treated with gemcitabine (DFS: P = 0.007, OS: P = 0.006). High cytoplasmic SPARC expression also was associated with worse patient outcome (DFS: P = 0.041, OS: P = 0.011). Again the effect was restricted to patients treated with gemcitabine (DFS: P = 0.002, OS: P = 0.003). In multivariable analysis, SPARC expression was independently predictive of patient outcome. Our data confirm the prognostic significance of SPARC expression after curatively intended resection. The negative prognostic impact was restricted to patients who received adjuvant treatment with gemcitabine, suggesting SPARC as a predictive marker for response to gemcitabine.Keywords
Funding Information
- Lilly Deutschland
This publication has 28 references indexed in Scilit:
- Cutoff Finder: A Comprehensive and Straightforward Web Application Enabling Rapid Biomarker Cutoff OptimizationPLOS ONE, 2012
- The Pancreas Cancer MicroenvironmentClinical Cancer Research, 2012
- nab-Paclitaxel Potentiates Gemcitabine Activity by Reducing Cytidine Deaminase Levels in a Mouse Model of Pancreatic CancerCancer Discovery, 2012
- Diverse biological functions of the SPARC family of proteinsThe International Journal of Biochemistry & Cell Biology, 2012
- Gemcitabine Plusnab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II TrialJournal of Clinical Oncology, 2011
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic CancerNew England Journal of Medicine, 2011
- Methylation of the SPARC gene promoter and its clinical implication in pancreatic cancerJournal of Experimental & Clinical Cancer Research, 2010
- Lack of host SPARC enhances vascular function and tumor spread in an orthotopic murine model of pancreatic carcinomaDisease Models & Mechanisms, 2010
- Osteonectin Influences Growth and Invasion of Pancreatic Cancer CellsAnnals of Surgery, 2005
- SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor–stromal interactionsOncogene, 2003